Cancer Immunotherapeutics In the News
Researchers at City of Hope, one of the largest cancer research and treatment organizations in the United States, will present late-breaking and clinical trial findings at this year’s American Association for Cancer Research Annual Meeting, which begins today. These additional presentations showcase a pilot program in tobacco use cessation and new developments in cell therapy.
A promising cure for a currently incurable disease — type 1 diabetes — is being developed at City of Hope, and patients can now apply for the Phase 1 trial. The trial treatment, PlpepTolDC, is designed to stop the autoimmune attack on the pancreatic islets, and should be more effective for those recently diagnosed.
City of Hope, one of the largest cancer research and treatment organizations in the United States, and Osel Inc., a company developing live biotherapeutic products for modulation of the human microbiome, today announced Phase 1 trial data showing that use of the live biotherapeutic CBM588 (Clostridium butyricum MIYAIRI 588® strain) plus immunotherapy medicine nivolumab/ipilimumab significantly improved progression-free survival in patients with metastatic kidney cancer when compared to use of nivolumab/ipilimumab alone. The study was published in Nature Medicine today.
City of Hope, a world-renowned cancer research and treatment organization, and CytoImmune Therapeutics, a clinical-stage immunotherapy company that is developing a novel class of natural killer (NK) cell-based cancer therapies, today announced a study published in the high-impact journal Gastroenterology that demonstrates off-the-shelf anti-prostate stem cell antigen (PSCA) chimeric antigen receptor (CAR) NK cells significantly suppressed pancreatic cancer in vitro and in vivo using a method known as freeze-thaw.
Enormous additions to our knowledge of human biology have opened the door to a potential “golden age” of cancer treatment. Here, we highlight five innovations that promise to dramatically shift the paradigm of oncology in the coming years, from targeted immunotherapies to the latest in radiation technology.
Data on a bispecific antibody for a form of non-Hodgkin lymphoma was presented at an American Society of Hematology annual meeting press briefing on Dec. 11. Patients within the City of Hope-led trial achieved high response rates, with 80% of patients responding positively to the treatment.
Data on bispecific antibody for a non-Hodgkin lymphoma presented today at an American Society of Hematology (ASH) Annual Meeting press briefing.
Abby Kanarak was diagnosed with nonsmall cell lung cancer and began taking Keytruda, which was designed to stop the action of PD-L1 so that the immune system can destroy the cancer.
In a global roundtable hosted by Bloomberg, Stone spoke of exciting innovations as well as the importance of increasing all patients’ access to groundbreaking treatments.